{"altmetric_id":4202063,"counts":{"readers":{"mendeley":10,"citeulike":0,"connotea":0},"total":{"posts_count":3},"policy":{"unique_users_count":1,"unique_users":["nap"],"posts_count":1},"twitter":{"unique_users_count":2,"unique_users":["fsgpme","Personal_Med"],"posts_count":2}},"citation":{"altmetric_jid":"4f6fa6333cf058f6100084a9","authors":["Garfeld S","Douglas MP","MacDonald KV","Marshall DA","Phillips KA","Susan Garfield"],"doi":"10.2217\/pme.14.74","endpage":"22","first_seen_on":"2015-06-23T17:23:35+00:00","issns":["1741-0541","1744-828X"],"issue":"1","journal":"Personalized Medicine","last_mentioned_on":1420564021,"links":["http:\/\/www.futuremedicine.com\/doi\/abs\/10.2217\/pme.14.74","http:\/\/dx.doi.org\/10.2217\/pme.14.74"],"pmcid":"PMC4303575","pmid":"25620993","pubdate":"2015-01-01T00:00:00+00:00","scopus_subjects":["Life Sciences","Medicine","Health Sciences","Pharmacology, Toxicology and Pharmaceutics","Biochemistry, Genetics and Molecular Biology"],"startpage":"13","title":"Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology.","type":"article","volume":"12","mendeley_url":"http:\/\/www.mendeley.com\/research\/consumer-familiarity-perspectives-expected-value-personalized-medicine-focus-applications-oncology"},"altmetric_score":{"score":4,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":4},"context_for_score":{"all":{"total_number_of_other_articles":7438587,"mean":6.4662340552314,"rank":1531193,"this_scored_higher_than_pct":78,"this_scored_higher_than":5857812,"rank_type":"exact","sample_size":7438587,"percentile":78},"similar_age_3m":{"total_number_of_other_articles":224475,"mean":8.0704499051116,"rank":56939,"this_scored_higher_than_pct":74,"this_scored_higher_than":166831,"rank_type":"exact","sample_size":224475,"percentile":74},"this_journal":{"total_number_of_other_articles":263,"mean":5.769786259542,"rank":67,"this_scored_higher_than_pct":72,"this_scored_higher_than":191,"rank_type":"exact","sample_size":263,"percentile":72},"similar_age_this_journal_3m":{"total_number_of_other_articles":21,"mean":3.599,"rank":3,"this_scored_higher_than_pct":80,"this_scored_higher_than":17,"rank_type":"exact","sample_size":21,"percentile":80}}},"demographics":{"poster_types":{"member_of_the_public":1,"science_communicator":1},"users":{"twitter":{"cohorts":{"Science communicators (journalists, bloggers, editors)":1,"Members of the public":1}},"mendeley":{"by_status":{"Student  > Ph. D. Student":3,"Student  > Postgraduate":1,"Student  > Master":1,"Student  > Bachelor":4,"Professor":1},"by_discipline":{"Materials Science":1,"Medicine and Dentistry":3,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":3,"Biochemistry, Genetics and Molecular Biology":1,"Arts and Humanities":1}}},"geo":{"mendeley":{"CU":1}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/fsgpme\/status\/552510645644832769","license":"datasift","citation_ids":[4202063],"posted_on":"2015-01-06T17:02:57+00:00","author":{"name":"Personalized Med Jnl","url":"http:\/\/t.co\/yBGzuYWQt8","image":"http:\/\/pbs.twimg.com\/profile_images\/494028120861597696\/eZDddbOC_normal.jpeg","description":"Personalized Medicine Journal | Addresses scientific, commercial and policy issues in Personalized Medicine | IF 1.336 | Published by Future Science Group","id_on_source":"fsgpme","tweeter_id":"2689469106","followers":749},"tweet_id":"552510645644832769"},{"url":"https:\/\/twitter.com\/Personal_Med\/status\/552511668375552001","license":"datasift","rt":["fsgpme"],"citation_ids":[4202063],"posted_on":"2015-01-06T17:07:01+00:00","author":{"name":"Personalized Med","image":"https:\/\/pbs.twimg.com\/profile_images\/1813421877\/pers_med_normal.jpg","description":"Up-to-the-minute reporting on developments in #PersonalizedMedicine","id_on_source":"Personal_Med","tweeter_id":"486807484","geo":{"lt":null,"ln":null},"followers":1353},"tweet_id":"552511668375552001"}],"policy":[{"title":"Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies: Workshop Summary","url":"https:\/\/www.nap.edu\/download\/21692","license":"public","citation_ids":[106710,2465608,512455,2647969,617027,738628,525476,710792,15049795,13364056,1908229,649328,2458771,1297242,2476725,15049798,15049800,233217,14501613,1263653,4202063,1974421,15049802,1763815,927140,2131480,2104635,3863397,3863397,3863397],"posted_on":"2015-01-01T00:00:00+00:00","source":{"name":"National Academies Press","description":"The US National Academies Press (NAP) was created by the National Academy of Sciences to publish the reports of the National Academies of Sciences, Engineering and Medicine, operating under a charter granted by the Congress of the United States. The NAP publishes on a wide range of topics in science, engineering, and medicine, providing authoritative information on important matters in science and health policy.","geo":{"country":"US"}},"page_url":"https:\/\/www.nap.edu\/catalog\/21692\/policy-issues-in-the-development-and-adoption-of-biomarkers-for-molecularly-targeted-cancer-therapies","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-9b8308f7165700415aacc77235d99238719ded0931d05306cdc9ba77dd4294fc.jpg"}}]}}